Because of the increased number of risk adjustment programs, improved diagnosis and treatment of chronic kidney disease (CKD) could trigger substantial financial benefit. This research maps a path for physicians and health systems to better utilize existing medications for their patients with CKD.
Precision Medicine Models
Two distinct entities will be created. The capabilities of the new US-Isaeli international partnership model are predicted to be a boon for oncologists and cancer therapeutics developers. It aims to untangle “medical mysteries in patients …”
Although Genomic Testing Cooperative’s agreement with New Jersey-based Hackensack Meridian Health is in its early stages, what is learned from the unique co-op model agreement will be useful for hospital and health system leaders who are evaluating precision medicine approaches.